What Flu Lab does

Flu Lab is a private philanthropic foundation founded in 2018 by Lucinda Southworth with a singular mission: to dramatically reduce the threat of influenza through bold, non-traditional approaches spanning prevention, treatment, diagnostics, and transmission-blocking. The organization is headquartered in the United States, operates with 11–50 staff, and is led by CEO Casey Wright (formerly of the CDC and HHS) and CTO Julie Schafer, PhD/MPH (formerly of BARDA and the White House National Security Council). Rather than developing its own products, Flu Lab functions as a catalytic capital allocator — combining philanthropic grants and direct venture investments to fund early-stage companies, academic research groups, and platform intermediaries across more than thirty countries.

The foundation's underlying technology footprint is its portfolio rather than an in-house platform. Core funded work covers universal and intranasal influenza vaccines (University of Oxford, Vivaldi Biosciences, Lavelle Lab, ENA Respiratory's INNA-051 nasal spray), antivirals (Panoplia Labs, Oxford RECOVERY FLU), diagnostics (Washington University breath-based test, Fishell Institute graphene biosensors, PicturaBio's imaging platform, Scout's Respiratory Scout, Detect's molecular tests), transmission science (Virginia Tech MITIGATE FLU, CTAP at Emory, Sentinel at the Broad Institute), and non-pharmaceutical interventions (Blueprint Biosecurity glycol vapors, Taza Aya plasma protection, Columbia far-UVC, UC Davis ventilation engineering). Flu Lab also backs ecosystem infrastructure such as the Center for Open Science, Protas for clinical trials, Intercept, and the Global Health Security Fund.

Flu Lab's business model is philanthropic rather than commercial: it distributes capital via grants and venture investments and does not sell products or services. Funding flows outbound — checked sizes range from roughly $100K seed grants to a $50M anchor commitment — to researchers, startups, nonprofits, and university centers selected for their potential to generate actionable knowledge against epidemic and pandemic influenza. The foundation markets its mission through its website, an active @TheFluLab Twitter presence, and earned coverage in outlets including MIT Technology Review, Newsweek, Emory News, the Washington Post, and the Journal of Infectious Diseases.

Name

Flu Lab

Legal name

Flu Lab

Website

https://theflulab.org

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Flu Lab is a private philanthropic foundation, founded in 2018 by Lucinda Southworth, that funds influenza research and innovation through grants and venture investments to researchers, startups, and academic institutions worldwide.

Ownership category

akta.pro rank

Product category

Philanthropic Research Funding

NAICS

Grantmaking and Giving Services (81321), Voluntary Health Organizations (813212)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Health & Medical Research Grantmaking Foundations (BPAGAKAL)

akta.pro secondary industries

Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA), Global Health Research, Evidence & Technical Assistance Organizations (HLAJAKAN)

Keywords

• Philanthropic research funding
• Influenza research grants
• Venture philanthropy
• Infectious disease investment
• Grantmaking foundation

Headquarters

HQ city

Not specified

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Operations, Personnel, Marketing or Sales, Others

Revenue model

1. Philanthropic funding model: Flu Lab is a philanthropic organization that funds influenza research and innovation through grants and venture investments rather than generating revenue from products or services. The organization seeks to help grantees and early-stage companies develop innovations that accelerate availability of new solutions for global influenza challenges.

Distribution channels1 record

Marketing channels3 records

Core offering

Flu Lab is a private philanthropic foundation that funds and advances innovative solutions to influenza challenges through strategic grants and venture investments. The organization does not develop its own products; instead, it evaluates prospective grants and investments based on their potential to create actionable knowledge and advance solutions across four priority areas: vaccines, therapeutics, diagnostics, and transmission-blocking interventions. Grantees include academic institutions, biotech startups, and nonprofits globally.

Product overview

Flu Lab is a philanthropic funding organization that does not develop or sell its own products. Instead, it funds and supports external organizations, researchers, and ventures working on influenza prevention, treatment, and research solutions through grants and venture investments. The organization acts as a grantmaker and investor rather than a product company.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• Funding organizations across vaccines, therapeutics, diagnostics, and transmission research
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• InterceptcoreStrategic or Co-development Partner · 1 June 2024Intercept is a nonprofit focused on countering the common cold and flu. Flu Lab is backing this effort as part of its mission to radically reduce the burden of respiratory infections. The partnership represents a $50,000,000 commitment announced in June 2024.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Wellcome Trust: One of the world's largest charitable foundations funding biomedical research and infectious disease R&D, including prior programmes on epidemic preparedness. Compares on funding model and disease-area overlap, but operates at materially greater asset scale.
• Bill & Melinda Gates Foundation: The largest philanthropic funder of global health and infectious disease R&D. Overlapping on vaccine/diagnostic/therapeutic priorities (including influenza historically), but operating at substantially greater scale and across a broader disease portfolio.
• Howard Hughes Medical Institute: Major biomedical research funder supporting investigator-driven science. Overlap in advancing fundamental infectious-disease mechanisms, though HHMI's primary vehicle is in-house investigator programmes rather than external grantmaking.

Direct peers

• Doris Duke Charitable Foundation: Family-founded foundation funding medical research and public health. Comparable on operating model, asset scale, and orientation toward high-conviction research grants.
• Schmidt Futures: Philanthropic vehicle of Eric and Wendy Schmidt supporting high-risk scientific talent and research, including biosecurity. Comparable as a tech-wealth-backed philanthropy funding bold, often pre-commercial science at scale.
• Audacious Project: Collective philanthropy initiative housed at TED that incubates and funds high-impact projects. Compares in pooling donor capital behind mission-focused bets, though typically across social issues beyond influenza.
• Open Philanthropy: Effective-altruism-aligned philanthropy that has made targeted grants in pandemic preparedness and biosecurity. Compares on grantmaking approach (high-conviction, large, mission-aligned bets) and visibility of scientific leadership.
• The Leona M. and Harry B. Helmsley Charitable Trust: Major US foundation funding biomedical research and global health programmes. Comparable scale and operating model (programmatic grantmaking with strategic special initiatives), with overlap on respiratory and infectious disease funding.
• Coalition for Epidemic Preparedness Innovations (CEPI): Global partnership that funds and coordinates development of vaccines against epidemic and pandemic threats. Directly comparable to Flu Lab in mission-focus on pathogen countermeasures and use of milestone-based grants across multiple development stages.

Emerging players

• Global Health Investment Corporation (GHIC): Impact-investing fund manager that Flu Lab itself backed via a USD 32M commitment. Comparable as a non-traditional funder bridging philanthropic and venture capital funding for global health products, with direct funding overlap.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/TheFluLab

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments5 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Flu Lab